Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000129518 | SCV000184294 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2025-02-18 | criteria provided, single submitter | clinical testing | The c.5153-16_5156del20insAATA variant results from a deletion of 20 nucleotides and an insertion of 4 nucleotides between positions 5153-16 and 5156 and involves the canonical splice acceptor site before coding exon 17 of the BRCA1 gene. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). The canonical splice acceptor site is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site, and may result in the creation or strengthening of a novel splice acceptor site; however, the exact impact of this deletion on BRCA1 splicing and function is currently unknown. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. |